pharmaceutical daily news

Novo Nordisk on Wednesday said that it has completed headline results of the phase 3a trials PIONEER 4 comparing oral semaglutide as a treatment for adults with type 2 diabetes to Victoza and placebo, as well as PIONEER 7 which had a goal to compare oral semaglutide once daily tablet,

Sanofi and Ablynx have completed the acquisition, as Sanofi has acquired all outstanding shares, warrants and convertible bonds of Ablynx.

Novartis’s eye care division Alcon unveils new data showing significantly improved near and intermediate distance vision with the AcrySof IQ PanOptix intraocular lens (IOL) compared to the Zeiss at Lisa tri 839MP IOL, which strengthen the value of the PanOptix IOL Enlighten optical technology, to provide enhanced image quality and more

Idorsia today is initiating a Phase 3 study React to test clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage, it said Monday.

Recipharm and Sanofi announced today that they have signed an agreement to transfer the Holmes Chapel site from global healthcare leader, Sanofi, to leading pharmaceutical contract development and manufacturing organisation, Recipharm.

TiGenix NV’s Chief Executive Officer, Eduardo Bravo will depart the board of directors and his role as CEO of TiGenix effective as of June 15, 2018, the company said Wednesday.

4D pharma has been cleared by the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Health Products Regulatory Authority (HPRA) to kick off the Phase II study of Blautix, 4D’s live biotherapeutic for the treatment of Irritable Bowel Syndrome (IBS), at sites in the UK and Ireland.

Santhera Pharmaceuticals said on Tuesday that the Korean Ministry of Food and Drug Safety (MFDS) has accepted its new drug application (NDA) for Raxone for review, regarding the treatment of Leber’s hereditary optic neuropathy (LHON). Raxone was granted orphan drug designation for LHON in South Korea.